Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Adaptive Biotechnologies and NeoGenomics have formed a multi-year exclusive commercial collaboration to enhance minimal residual disease (MRD) monitoring for select blood cancers. Adaptive’s FDA-cleared clonoSEQ test, which uses next-generation sequencing to detect MRD in lymphoid cancers, will integrate with NeoGenomics’ COMPASS and CHART testing services.